A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Eli Lilly and Company
201 participants
Apr 23, 2025
INTERVENTIONAL
Conditions
Summary
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.
Eligibility
Inclusion Criteria12
- Have no significant body weight change for the 3 months prior to screening
- Part A and Part E:
- Are considered healthy
- Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening
- Part B:
- Have a BMI of 27 to 45 kg/m2 at screening
- Part C:
- Have a BMI of 25 to 45 kg/m2 at screening
- Part D:
- Have type 2 diabetes
- Have hemoglobin A1C (HbA1c) ≥7.0% and ≤10.5% at screening
- Have a BMI of 27 to 45 kg/m2 at screening
Exclusion Criteria7
- Have had an acute cardiovascular condition within the past 6 months prior to screening
- Have liver disease or pancreatitis
- Have used medications for weight loss within the 3 months prior to screening
- Parts A, B, C, E:
- Have any form of diabetes
- Part D:
- Have type 1 diabetes
Interventions
Administered orally
Administered orally
Administered IV
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06945419